PURPOSE: To determine the local recurrence rate and factors associated with recurrence after intraoperative ablation of colorectal cancer liver metastases. METHODS: A retrospective analysis of a prospectively maintained database was performed for patients who underwent ablation of a hepatic colorectal cancer metastasis in the operating room from April 1996 to March 2010. Kaplan-Meier survival curves and Cox models were used to determine recurrence rates and assess significance. RESULTS: Ablation was performed in 10% (n = 158 patients) of all cases during the study period. Seventy-eight percent were performed in conjunction with a liver resection. Of the 315 tumors ablated, most tumors were ≤ 1 cm in maximum diameter (53%). Radiofrequency ablation was used to treat most of the tumors (70%). Thirty-six tumors (11%) had local recurrence as part of their recurrence pattern. Disease recurred in the liver or systemically after 212 tumors (67%) were ablated. On univariate analysis, tumor size greater than 1 cm was associated with a significantly increased risk of local recurrence (hazard ratio 2.3, 95% confidence interval 1.2-4.5, P = 0.013). The 2 year ablation zone recurrence-free survival was 92% for tumors ≤ 1 cm compared to 81% for tumors >1 cm. On multivariate analysis, tumor size of >1 cm, lack of postoperative chemotherapy, and use of cryotherapy were significantly associated with a higher local recurrence rate. CONCLUSIONS: Intraoperative ablation appears to be highly effective treatment for hepatic colorectal tumors ≤ 1 cm.
PURPOSE: To determine the local recurrence rate and factors associated with recurrence after intraoperative ablation of colorectal cancer liver metastases. METHODS: A retrospective analysis of a prospectively maintained database was performed for patients who underwent ablation of a hepatic colorectal cancer metastasis in the operating room from April 1996 to March 2010. Kaplan-Meier survival curves and Cox models were used to determine recurrence rates and assess significance. RESULTS: Ablation was performed in 10% (n = 158 patients) of all cases during the study period. Seventy-eight percent were performed in conjunction with a liver resection. Of the 315 tumors ablated, most tumors were ≤ 1 cm in maximum diameter (53%). Radiofrequency ablation was used to treat most of the tumors (70%). Thirty-six tumors (11%) had local recurrence as part of their recurrence pattern. Disease recurred in the liver or systemically after 212 tumors (67%) were ablated. On univariate analysis, tumor size greater than 1 cm was associated with a significantly increased risk of local recurrence (hazard ratio 2.3, 95% confidence interval 1.2-4.5, P = 0.013). The 2 year ablation zone recurrence-free survival was 92% for tumors ≤ 1 cm compared to 81% for tumors >1 cm. On multivariate analysis, tumor size of >1 cm, lack of postoperative chemotherapy, and use of cryotherapy were significantly associated with a higher local recurrence rate. CONCLUSIONS: Intraoperative ablation appears to be highly effective treatment for hepatic colorectal tumors ≤ 1 cm.
Authors: Eddie K Abdalla; Todd W Bauer; Yun S Chun; Michael D'Angelica; David A Kooby; William R Jarnagin Journal: HPB (Oxford) Date: 2013-02 Impact factor: 3.647
Authors: U Leung; D Kuk; M I D'Angelica; T P Kingham; P J Allen; R P DeMatteo; W R Jarnagin; Y Fong Journal: Br J Surg Date: 2014-10-09 Impact factor: 6.939
Authors: Oliver S Eng; Ashley T Tsang; Dirk Moore; Chunxia Chen; Sumana Narayanan; Christopher J Gannon; David A August; Darren R Carpizo; Laleh G Melstrom Journal: J Surg Oncol Date: 2014-12-29 Impact factor: 3.454
Authors: Sho Fujisawa; Yevgeniy Romin; Afsar Barlas; Lydia M Petrovic; Mesruh Turkekul; Ning Fan; Ke Xu; Alessandra R Garcia; Sebastien Monette; David S Klimstra; Joseph P Erinjeri; Stephen B Solomon; Katia Manova-Todorova; Constantinos T Sofocleous Journal: Cytotechnology Date: 2013-09-25 Impact factor: 2.058
Authors: K M Govaert; C S van Kessel; E J A Steller; B L Emmink; I Q Molenaar; O Kranenburg; R van Hillegersberg; I H M Borel Rinkes Journal: J Gastrointest Surg Date: 2014-01-29 Impact factor: 3.452